ImmVira Overview
- Year Founded
-
2015
- Status
-
IPO Registration
- Employees
-
78
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
23
ImmVira General Information
Description
Developer of biopharmaceutical technology in the field of immunotherapy designed to provide medical solutions to treat cancer and tumor. The company operates as a biotechnology platform focused on the development of oncolytic viruses and vector-type approaches for the treatment of cancer and its products include genetically engineered Oncolytic Herpes Simplex Virus that target metastatic tumors or tumors inaccessible by direct injection, thereby enabling patients to receive better tumor treatment and solutions.
Contact Information
Website
www.immviragroup.comCorporate Office
- 3F, Block B, Building 1, Yinxing Zhijie II, Guanlan Street
- Longhua District
- Shenzhen, Guangdong 518000
- China
Corporate Office
- 3F, Block B, Building 1, Yinxing Zhijie II, Guanlan Street
- Longhua District
- Shenzhen, Guangdong 518000
- China
ImmVira Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. IPO | 04-Jul-2025 | Announced | Clinical Trials - General | |||
| 9. Secondary Transaction - Private | 09-Jan-2024 | Completed | Clinical Trials - General | |||
| 8. Later Stage VC (Series C1) | 30-Sep-2022 | Completed | Clinical Trials - General | |||
| 7. Later Stage VC (Series C) | 29-Dec-2020 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC (Series B1) | 23-Sep-2020 | Completed | Clinical Trials - General | |||
| 5. Early Stage VC (Series B) | 12-Jun-2020 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series A1) | 24-Dec-2018 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series A2) | 22-May-2017 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A1) | 22-Jun-2016 | $3.81M | $3.81M | Completed | Generating Revenue | |
| 1. University Spin-Out | 28-May-2015 | Completed | Startup |
ImmVira Comparisons
Industry
Financing
Details
ImmVira Competitors (3)
One of ImmVira’s 3 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA |
ImmVira Patents
ImmVira Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4820556-A1 | Methods for detecting an anti-hsv antibody in a sample | Pending | 06-Dec-2023 | ||
| AU-2023319760-A1 | Replication incompetent herpes simplex virus type 1 viral vaccine | Pending | 05-Aug-2022 | ||
| EP-4565270-A1 | Replication incompetent herpes simplex virus type 1 viral vaccine | Pending | 05-Aug-2022 | ||
| EP-4565270-A4 | Replication incompetent herpes simplex virus type 1 viral vaccine | Pending | 05-Aug-2022 | ||
| US-20260335432-A1 | Replication incompetent herpes simplex virus type 1 viral vaccine | Pending | 05-Aug-2022 | A61K39/245 |
ImmVira Signals
ImmVira Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| OBiO Technology | Corporation | Minority | ||
| China Merchants China Direct Investments | PE/Buyout | Minority | ||
| Gandao Investment Holding Company | Asset Manager | Minority | ||
| GP Capital (Shanghai) | PE/Buyout | Minority | ||
| China Merchants Venture Capital | Corporate Venture Capital | Minority |
ImmVira FAQs
-
When was ImmVira founded?
ImmVira was founded in 2015.
-
Where is ImmVira headquartered?
ImmVira is headquartered in Shenzhen, China.
-
What is the size of ImmVira?
ImmVira has 78 total employees.
-
What industry is ImmVira in?
ImmVira’s primary industry is Drug Discovery.
-
Is ImmVira a private or public company?
ImmVira is a Private company.
-
What is ImmVira’s current revenue?
The current revenue for ImmVira is .
-
How much funding has ImmVira raised over time?
ImmVira has raised $146M.
-
Who are ImmVira’s investors?
OBiO Technology, China Merchants China Direct Investments, Gandao Investment Holding Company, GP Capital (Shanghai), and China Merchants Venture Capital are 5 of 23 investors who have invested in ImmVira.
-
Who are ImmVira’s competitors?
Inovio Pharmaceuticals, Kite Pharma, and Genetix Biotherapeutics are competitors of ImmVira.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process